A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis.

Abstract	A PtIV prodrug (PDMA) exhibits great potential for the therapy of metastatic triple-negative breast cancer (TNBC) through a synergistic action of antiangiogensis and antimetastasis.
Authors	Yan Guo , Shuren Zhang , Hao Yuan , Dongfan Song , Suxing Jin , Zijian Guo , Xiaoyong Wang
Journal	Dalton transactions (Cambridge, England : 2003) (Dalton Trans) Vol. 48 Issue 11 Pg. 3571-3575 (Mar 12 2019) ISSN: 1477-9234 [Electronic] England
PMID	30793153 (Publication Type: Journal Article)
Chemical References	Antineoplastic Agents Organoplatinum Compounds Prodrugs
Topics	Antineoplastic Agents (chemistry, pharmacology) Cell Proliferation (drug effects) DNA Damage Female Humans Molecular Structure Neoplasm Metastasis (prevention & control) Organoplatinum Compounds (chemistry, pharmacology) Prodrugs (chemistry, pharmacology) Triple Negative Breast Neoplasms (blood supply, drug therapy, pathology, secondary)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!